George C Tsokos

List of Publications by Year
in descending order

527 papers	27,279 citations	7551 77 h-index	13338 130 g-index
569 all docs	569 docs citations	569 times ranked	21315 citing authors

#	Article	IF	Citations
1	Systemic Lupus Erythematosus. New England Journal of Medicine, 2011, 365, 2110-2121.	13.9	2,265
2	Heat Shock Protein 70 kDa Molecular Biology, Biochemistry, and Physiology. , 1998, 80, 183-201.		1,010
3	New insights into the immunopathogenesis of systemic lupus erythematosus. Nature Reviews Rheumatology, 2016, 12, 716-730.	3.5	909
4	Expanded Double Negative T Cells in Patients with Systemic Lupus Erythematosus Produce IL-17 and Infiltrate the Kidneys. Journal of Immunology, 2008, 181, 8761-8766.	0.4	678
5	Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective. Trends in Molecular Medicine, 2017, 23, 615-635.	3.5	328
6	Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in Molecular Medicine, 2010, 16, 47-57.	3.5	311
7	Autoimmunity and organ damage in systemic lupus erythematosus. Nature Immunology, 2020, 21, 605-614.	7.0	294
8	The Role of IL-23/IL-17 Axis in Lupus Nephritis. Journal of Immunology, 2009, 183, 3160-3169.	0.4	268
9	Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet, The, 2018, 392, 1330-1339.	6.3	244
10	T cells as therapeutic targets in SLE. Nature Reviews Rheumatology, 2010, 6, 317-325.	3.5	230
11	Regulatory T cells in the treatment of disease. Nature Reviews Drug Discovery, 2018, 17, 823-844.	21.5	224
12	Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Annals of the Rheumatic Diseases, 2016, 75, 2014-2021.	0.5	200
13	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. Journal of Clinical Investigation, 2005, 115, 996-1005.	3.9	199
14	Phosphatase PP2A is requisite for the function of regulatory T cells. Nature Immunology, 2016, 17, 556-564.	7.0	191
15	Molecular Basis of Deficient IL-2 Production in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2001, 166, 4216-4222.	0.4	188
16	T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. Journal of Clinical Investigation, 2015, 125, 2220-2227.	3.9	185
17	Glutathione peroxidase 4â€“regulated neutrophil ferroptosis induces systemic autoimmunity. Nature Immunology, 2021, 22, 1107-1117.	7.0	185
18	CaMK4-dependent activation of AKT/mTOR and CREM-Î± underlies autoimmunity-associated Th17 imbalance. Journal of Clinical Investigation, 2014, 124, 2234-2245.	3.9	185

#	Article	IF	Citations
19	Cutting Edge: IL-23 Receptor Deficiency Prevents the Development of Lupus Nephritis in C57BL/6â€“lpr/lpr Mice. Journal of Immunology, 2010, 184, 4605-4609.	0.4	175
20	T cell metabolism: new insights in systemic lupus erythematosus pathogenesis and therapy. Nature Reviews Rheumatology, 2020, 16, 100-112.	3.5	174
21	Microglia-dependent synapse loss in type I interferon-mediated lupus. Nature, 2017, 546, 539-543.	13.7	173
22	Alterations in Lipid Raft Composition and Dynamics Contribute to Abnormal T Cell Responses in Systemic Lupus Erythematosus. Journal of Immunology, 2004, 172, 7821-7831.	0.4	172
23	Mechanisms of Immune Complexâ€“Mediated Neutrophil Recruitment and Tissue Injury. Circulation, 2009, 120, 2012-2024.	1.6	171
24	Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 1088.	2.2	170
25	Phosphorylated ERM Is Responsible for Increased T Cell Polarization, Adhesion, and Migration in Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 1938-1947.	0.4	169
26	Mice Deficient in Complement Receptors 1 and 2 Lack a Tissue Injury-Inducing Subset of the Natural Antibody Repertoire. Journal of Immunology, 2002, 169, 2126-2133.	0.4	165
27	Fc? receptor type I ? chain replaces the deficient T cell receptor ? chain in T cells of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2001, 44, 1114-1121.	6.7	158
28	Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Research and Therapy, 2011, 13, 207.	1.6	157
29	Human TCR-Î±Î²+ CD4â^' CD8â^' T Cells Can Derive from CD8+ T Cells and Display an Inflammatory Effector Phenotype. Journal of Immunology, 2009, 183, 4675-4681.	0.4	154
30	Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases. Trends in Molecular Medicine, 2011, 17, 714-724.	3.5	154
31	Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. Journal of Clinical Investigation, 2005, 115, 2444-2453.	3.9	153
32	T cells in Systemic Lupus Erythematosus. Current Opinion in Immunology, 2016, 43, 32-38.	2.4	150
33	Stat3 promotes IL-10 expression in lupus T cells through trans- activation and chromatin remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13457-13462.	3.3	148
34	Renal and Metabolic Complications of Undifferentiated and Lymphoblastic Lymphomas. Medicine (United States), 1981, 60, 218-229.	0.4	143
35	Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 1139-1154.	6.7	141
36	Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Current Opinion in Rheumatology, 2005, 17, 550-557.	2.0	136

#	Article	IF	Citations
37	Protein phosphatase 2A is a negative regulator of IL-2 production in patients with systemic lupus erythematosus. Journal of Clinical Investigation, 2005, 115, 3193-3204.	3.9	134
38	Suppression of skin and kidney disease by inhibition of spleen tyrosine kinase in lupusâ€prone mice. Arthritis and Rheumatism, 2010, 62, 2086-2092.	6.7	125
39	cAMP-responsive Element Modulator (CREM)Î± Protein Induces Interleukin 17A Expression and Mediates Epigenetic Alterations at the Interleukin-17A Gene Locus in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 43437-43446.	1.6	122
40	The IL-2 Defect in Systemic Lupus Erythematosus Disease Has an Expansive Effect on Host Immunity. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-6.	3.0	120
41	The Dysregulation of Cytokine Networks in Systemic Lupus Erythematosus. Journal of Interferon and Cytokine Research, 2011, 31, 769-779.	0.5	120
42	Pathogenic Natural Antibodies Recognizing Annexin IV Are Required to Develop Intestinal Ischemia-Reperfusion Injury. Journal of Immunology, 2009, 182, 5363-5373.	0.4	116
43	An Autoimmunogenic and Proinflammatory Profile Defined by the Gut Microbiota of Patients With Untreated Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 232-243.	2.9	115
44	The FcRÎ³ Subunit and Syk Kinase Replace the CD3Î¶-Chain and ZAP-70 Kinase in the TCR Signaling Complex of Human Effector CD4 T Cells. Journal of Immunology, 2003, 170, 4189-4195.	0.4	113
45	Human Complement Receptor Type 1/CD35 Is an Epstein-Barr Virus Receptor. Cell Reports, 2013, 3, 371-385.	2.9	113
46	Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV. Journal of Clinical Investigation, 2005, 115, 996-1005.	3.9	109
47	Immune cell signaling defects in lupus: activation, anergy and death. Trends in Immunology, 1999, 20, 119-124.	7.5	108
48	T cells and autoimmune kidney disease. Nature Reviews Nephrology, 2017, 13, 329-343.	4.1	106
49	IL-2 Protects Lupus-Prone Mice from Multiple End-Organ Damage by Limiting CD4â^'CD8â^' IL-17â€"Producing T Cells. Journal of Immunology, 2014, 193, 2168-2177.	0.4	105
50	Rewiring the T-cell: signaling defects and novel prospects for the treatment of SLE. Trends in Immunology, 2003, 24, 259-263.	2.9	104
51	Reconstitution of deficient T cell receptor ? chain restores T cell signaling and augments T cell receptor/CD3-induced interleukin-2 production in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2003, 48, 1948-1955.	6.7	103
52	Defective CD3-Mediated Cell Death in Activated T Cells from Patients with Systemic Lupus Erythematosus: Role of Decreased Intracellular TNF-Î±. Clinical Immunology and Immunopathology, 1996, 81, 293-302.	2.1	102
53	The CD38/NAD/SIRTUIN1/EZH2 Axis Mitigates Cytotoxic CD8ÂT Cell Function and Identifies Patients with SLE Prone to Infections. Cell Reports, 2020, 30, 112-123.e4.	2.9	102
54	B cellâ€"intrinsic deficiency of the Wiskott-Aldrich syndrome protein (WASp) causes severe abnormalities of the peripheral B-cell compartment in mice. Blood, 2012, 119, 2819-2828.	0.6	99

#	Article	IF	Citations
55	Gene-function studies in systemic lupus erythematosus. Nature Reviews Rheumatology, 2013, 9, 476-484.	3.5	99
56	Differential Expression and Molecular Associations of Syk in Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2008, 181, 8145-8152.	0.4	97
57	SLAM family receptors and the SLAM-associated protein (SAP) modulate T cell functions. Seminars in Immunopathology, 2010, 32, 157-171.	2.8	96
58	Cholera Toxin B Accelerates Disease Progression in Lupus-Prone Mice by Promoting Lipid Raft Aggregation. Journal of Immunology, 2008, 181, 4019-4026.	0.4	95
59	Induction of the CTLA-4 Gene in Human Lymphocytes Is Dependent on NFAT Binding the Proximal Promoter. Journal of Immunology, 2007, 179, 3831-3840.	0.4	94
60	Antisense Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Up-Regulates IL-2 in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2002, 169, 4147-4152.	0.4	93
61	cAMP response element modulator Î± controls IL2 and IL17A expression during CD4 lineage commitment and subset distribution in lupus. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 16606-16611.	3.3	92
62	How signaling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends in Immunology, 2008, 29, 110-115.	2.9	91
63	Calcium/Calmodulin-Dependent Protein Kinase IV Suppresses IL-2 Production and Regulatory T Cell Activity in Lupus. Journal of Immunology, 2012, 189, 3490-3496.	0.4	91
64	The Catalytic Subunit of Protein Phosphatase 2A (PP2Ac) Promotes DNA Hypomethylation by Suppressing the Phosphorylated Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (ERK) Kinase (MEK)/Phosphorylated ERK/DNMT1 Protein Pathway in T-cells from Controls and Systemic Lupus Erythematosus Patients. Journal of Biological Chemistry, 2013, 288, 21936-21944.	1.6	91
65	Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmunity Reviews, 2009, 8, 190-195.	2.5	89
66	T cells and IL-17 in lupus nephritis. Clinical Immunology, 2017, 185, 95-99.	1.4	89
67	Suppression of autoimmunity and organ pathology in lupusâ€prone mice upon inhibition of calcium/calmodulinâ€dependent protein kinase type IV. Arthritis and Rheumatism, 2011, 63, 523-529.	6.7	87
68	Complement Receptor 1 Is a Sialic Acid-Independent Erythrocyte Receptor of Plasmodium falciparum. PLoS Pathogens, 2010, 6, e1000968.	2.1	86
69	DNA methylation in systemic lupus erythematosus. Epigenomics, 2017, 9, 505-525.	1.0	86
70	Overexpression of HSPâ€70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity. FASEB Journal, 1998, 12, 451-459.	0.2	84
71	Anti-Phospholipid Antibodies Restore Mesenteric Ischemia/Reperfusion-Induced Injury in Complement Receptor 2/Complement Receptor 1-Deficient Mice. Journal of Immunology, 2004, 173, 7055-7061.	0.4	84
72	Depletion of gut commensal bacteria attenuates intestinal ischemia/reperfusion injury. American Journal of Physiology - Renal Physiology, 2011, 301, G1020-G1030.	1.6	83

#	Article	IF	Citations
73	Deletion of microRNA-155 reduces autoantibody responses and alleviates lupus-like disease in theFas^{lpr}mouse. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 20194-20199.	3.3	83
74	IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus. Journal of Immunology, 2017, 199, 903-910.	0.4	83
75	Immunodeficiency and autoimmunity: lessons from systemic lupus erythematosus. Trends in Molecular Medicine, 2012, 18, 101-108.	3.5	82
76	IL-17 in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-4.	3.0	81
77	cAMP-responsive Element Modulator (CREM)Î± Protein Signaling Mediates Epigenetic Remodeling of the Human Interleukin-2 Gene. Journal of Biological Chemistry, 2011, 286, 43429-43436.	1.6	81
78	Immune cells and cytokines in systemic lupus erythematosus: an update. Current Opinion in Rheumatology, 2005, 17, 518-522.	2.0	80
79	Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity, 2007, 40, 1-8.	1.2	80
80	Interleukin-17-producing T cells in lupus. Current Opinion in Rheumatology, 2010, 22, 499-503.	2.0	80
81	CaMK4 compromises podocyte function in autoimmune and nonautoimmune kidney disease. Journal of Clinical Investigation, 2018, 128, 3445-3459.	3.9	80
82	Increased Levels of NF-ATc2 Differentially Regulate CD154 and IL-2 Genes in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2007, 178, 1960-1966.	0.4	79
83	Transcriptional factor ICER promotes glutaminolysis and the generation of Th17 cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 2478-2483.	3.3	79
84	Pyruvate kinase M2 is requisite for Th1 and Th17 differentiation. JCI Insight, 2019, 4, .	2.3	79
85	Complement, natural antibodies, autoantibodies and tissue injury. Autoimmunity Reviews, 2006, 5, 89-92.	2.5	77
86	IL-17 producing CD4+ T cells mediate accelerated ischemia/reperfusion-induced injury in autoimmunity-prone mice. Clinical Immunology, 2009, 130, 313-321.	1.4	77
87	cAMP responsive element modulator: a critical regulator of cytokine production. Trends in Molecular Medicine, 2013, 19, 262-269.	3.5	77
88	Protein Phosphatase 2A Enables Expression of Interleukin 17 (IL-17) through Chromatin Remodeling. Journal of Biological Chemistry, 2013, 288, 26775-26784.	1.6	77
89	B Cells, Be Gone â€" B-Cell Depletion in the Treatment of Rheumatoid Arthritis. New England Journal of Medicine, 2004, 350, 2546-2548.	13.9	76
90	Expression of CD44 variant isoforms CD44v3 and CD44v6 is increased on T cells from patients with systemic lupus erythematosus and is correlated with disease activity. Arthritis and Rheumatism, 2010, 62, 1431-1437.	6.7	76

#	Article	IF	Citations
91	Essential role for the prolyl isomerase Pin1 in Toll-like receptor signaling and type I interferonâ€“mediated immunity. Nature Immunology, 2011, 12, 733-741.	7.0	76
92	Complement Inhibitor, Complement Receptor 1-Related Gene/Protein y-Ig Attenuates Intestinal Damage After the Onset of Mesenteric Ischemia/Reperfusion Injury in Mice. Journal of Immunology, 2001, 167, 5921-5927.	0.4	75
93	The Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Suppresses IL-2 Production in Stimulated T Cells by a Chromatin-Dependent Mechanism. Journal of Immunology, 2003, 170, 2971-2976.	0.4	75
94	Cyclic Adenosine 5â€²-Monophosphate Response Element Modulator Is Responsible for the Decreased Expression of c-fos and Activator Protein-1 Binding in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2004, 173, 3557-3563.	0.4	74
95	Single-cell sequencing of immune cells from anticitrullinated peptide antibody positive and negative rheumatoid arthritis. Nature Communications, 2021, 12, 4977.	5.8	73
96	Phosphorylation and O-Linked Glycosylation of Elf-1 Leads to Its Translocation to the Nucleus and Binding to the Promoter of the TCR Î¶-Chain. Journal of Immunology, 2002, 168, 2865-2871.	0.4	72
97	Immunopathogenesis of ischemia/reperfusion-associated tissue damage. Clinical Immunology, 2011, 141, 3-14.	1.4	72
98	Polymorphisms/Mutations of TCR-Î¶-Chain Promoter and 3â€² Untranslated Region and Selective Expression of TCR Î¶-Chain with an Alternatively Spliced 3â€² Untranslated Region in Patients with Systemic Lupus Erythematosus. Journal of Autoimmunity, 2001, 16, 133-142.	3.0	71
99	Transcriptional Activation of the Human Inducible Nitric-oxide Synthase Promoter by KrÃ¼ppel-like Factor 6. Journal of Biological Chemistry, 2003, 278, 14812-14819.	1.6	71
100	Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity. Nature Communications, 2020, 11, 6149.	5.8	71
101	Defective FcÎ³RIIb1 Signaling Contributes to Enhanced Calcium Response in B Cells from Patients with Systemic Lupus Erythematosus. Clinical Immunology, 2001, 101, 130-135.	1.4	70
102	ZAP-70 and SLP-76 Regulate Protein Kinase C-Î¸ and NF-ÎºB Activation in Response to Engagement of CD3 and CD28. Journal of Immunology, 2001, 166, 5654-5664.	0.4	70
103	Methylation Status of CpG Islands Flanking a cAMP Response Element Motif on the Protein Phosphatase 2Acα Promoter Determines CREB Binding and Activity. Journal of Immunology, 2009, 182, 1500-1508.	0.4	70
104	Decreased Stability and Translation of T Cell Receptor Î¶ mRNA with an Alternatively Spliced 3â€²-Untranslated Region Contribute to Î¶ Chain Down-regulation in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2005, 280, 18959-18966.	1.6	68
105	Intracellular Activation of Complement 3 Is Responsible for Intestinal Tissue Damage during Mesenteric Ischemia. Journal of Immunology, 2017, 198, 788-797.	0.4	68
106	Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3Î¶ expression. Blood, 2001, 97, 3851-3859.	0.6	67
107	T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor ? chain messenger RNA. Arthritis and Rheumatism, 2001, 44, 1336-1350.	6.7	67
108	Increased Caspase-3 Expression and Activity Contribute to Reduced CD3Î¶ Expression in Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2005, 175, 3417-3423.	0.4	67

#	Article	IF	Citations
109	Cutting Edge: Calcium/Calmodulin-Dependent Protein Kinase Type IV Is Essential for Mesangial Cell Proliferation and Lupus Nephritis. Journal of Immunology, 2011, 187, 5500-5504.	0.4	66
110	cAMP Responsive Element Modulator (CREM) Î± Mediates Chromatin Remodeling of CD8 during the Generation of CD3+CD4â^'CD8â^' T Cells. Journal of Biological Chemistry, 2014, 289, 2361-2370.	1.6	66
111	Glutaminase 1 Inhibition Reduces Glycolysis and Ameliorates Lupusâ€like Disease in <scp>MRL</scp>/lpr Mice and Experimental Autoimmune Encephalomyelitis. Arthritis and Rheumatology, 2019, 71, 1869-1878.	2.9	66
112	Circulating Intercellular Adhesion Molecule-1 in Patients with Systemic Sclerosis. Clinical Immunology and Immunopathology, 1993, 68, 88-92.	2.1	65
113	Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Research and Therapy, 2010, 12, 222.	1.6	65
114	Promoter Hypomethylation Results in Increased Expression of Protein Phosphatase 2A in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Immunology, 2011, 186, 4508-4517.	0.4	65
115	Increased Expression of SLAM Receptors SLAMF3 and SLAMF6 in Systemic Lupus Erythematosus T Lymphocytes Promotes Th17 Differentiation. Journal of Immunology, 2012, 188, 1206-1212.	0.4	65
116	ICER is requisite for Th17 differentiation. Nature Communications, 2016, 7, 12993.	5.8	64
117	Molecular aberrations in human systemic lupus erythematosus. Trends in Molecular Medicine, 2000, 6, 418-424.	2.6	63
118	Cytosolic DNA-Activated Human Dendritic Cells Are Potent Activators of the Adaptive Immune Response. Journal of Immunology, 2011, 187, 1222-1234.	0.4	63
119	Signaling Lymphocytic Activation Molecule Family Member 7 Engagement Restores Defective Effector CD8+ T Cell Function in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2017, 69, 1035-1044.	2.9	63
120	Deficient Î³-interferon production in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1986, 29, 1210-1215.	6.7	62
121	Targeting Syk in Autoimmune Rheumatic Diseases. Frontiers in Immunology, 2016, 7, 78.	2.2	62
122	Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. International Immunology, 1990, 2, 651-659.	1.8	61
123	Increased Expression of Functional Fas-Ligand in Activated T Cells from Patients with Systemic Lupus Erythematosus. Autoimmunity, 1997, 25, 213-221.	1.2	61
124	Antiinflammatory Effects of Soluble Complement Receptor Type 1 Promote Rapid Recovery of Ischemia/Reperfusion Injury in Rat Small Intestine. Clinical Immunology, 1999, 90, 266-275.	1.4	61
125	Calcium signaling in systemic lupus erythematosus T cells: A treatment target. Arthritis and Rheumatism, 2011, 63, 2058-2066.	6.7	61
126	cAMP-responsive Element Modulator Î± (CREMÎ±) Suppresses IL-17F Protein Expression in T Lymphocytes from Patients with Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 4715-4725.	1.6	61

#	Article	IF	Citations
127	The Transcriptional Repressor cAMP Response Element Modulator Î± Interacts with Histone Deacetylase 1 to Repress Promoter Activity. Journal of Immunology, 2006, 177, 6159-6164.	0.4	60
128	KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3⁺regulatory T cells in MRL/lprmice. Autoimmunity, 2014, 47, 445-450.	1.2	60
129	Immune cell signaling in lupus. Current Opinion in Rheumatology, 2000, 12, 355-363.	2.0	59
130	Epigenetic regulation of cytokine expression in systemic lupus erythematosus with special focus on T cells. Autoimmunity, 2014, 47, 234-241.	1.2	59
131	Systemic lupus erythematosus favors the generation of IL-17 producing double negative T cells. Nature Communications, 2020, 11, 2859.	5.8	59
132	Splicing factor SRSF1 controls T cell hyperactivity and systemic autoimmunity. Journal of Clinical Investigation, 2019, 129, 5411-5423.	3.9	59
133	Interleukin-2 and regulatory T cells in rheumatic diseases. Nature Reviews Rheumatology, 2021, 17, 749-766.	3.5	59
134	Immunohistological Demonstration of Transforming Growth Factor-Î² Isoforms in the Skin of Patients with Systemic Sclerosis. Clinical Immunology and Immunopathology, 1993, 69, 199-204.	2.1	58
135	Abnormal expression of various molecular forms and distribution of T cell receptor ? chain in patients with systemic lupus erythematosus. Arthritis and Rheumatism, 2002, 46, 163-174.	6.7	58
136	The role of T cells in systemic lupus erythematosus. Current Opinion in Rheumatology, 2014, 26, 493-501.	2.0	58
137	Defective antigen-presenting cell function in patients with systemic lupus erythematosus: Role of the B7-1 (CD80) costimulatory molecule. Arthritis and Rheumatism, 1996, 39, 600-609.	6.7	57
138	T Cell Rewiring in Differentiation and Disease. Journal of Immunology, 2003, 171, 3325-3331.	0.4	57
139	Human Lupus Serum Induces Neutrophil-Mediated Organ Damage in Mice That Is Enabled by Mac-1 Deficiency. Journal of Immunology, 2012, 189, 3714-3723.	0.4	57
140	Protein Kinase C-Î¸ Participates in the Activation of Cyclic AMP-Responsive Element-Binding Protein and Its Subsequent Binding to the â^'180 Site of the IL-2 Promoter in Normal Human T Lymphocytes. Journal of Immunology, 2001, 166, 5665-5674.	0.4	56
141	Targeting Regulatory T Cells to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2018, 9, 786.	2.2	56
142	A High-Content Screen for Mucin-1-Reducing Compounds Identifies Fostamatinib as a Candidate for Rapid Repurposing for Acute Lung Injury. Cell Reports Medicine, 2020, 1, 100137.	3.3	56
143	Deficiency of base excision repair enzyme NEIL3 drives increased predisposition to autoimmunity. Journal of Clinical Investigation, 2016, 126, 4219-4236.	3.9	56
144	Inhibition of SHP2 ameliorates the pathogenesis of systemic lupus erythematosus. Journal of Clinical Investigation, 2016, 126, 2077-2092.	3.9	56

#	Article	IF	Citations
145	Pituitary-Adrenal Responsiveness to Corticotropin-Releasing Hormone in Patients Receiving Chronic, Alternate Day Glucocorticoid Therapy*. Journal of Clinical Endocrinology and Metabolism, 1985, 61, 22-27.	1.8	55
146	Transcriptional Activation of the cAMP-responsive Modulator Promoter in Human T Cells Is Regulated by Protein Phosphatase 2A-mediated Dephosphorylation of SP-1 and Reflects Disease Activity in Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 1795-1801.	1.6	55
147	Complement 3d: From molecular adjuvant to target of immune escape mechanisms. Clinical Immunology, 2006, 121, 177-185.	1.4	54
148	Cellâ€Derived Extracellular Matrixâ€Rich Biomimetic Substrate Supports Podocyte Proliferation, Differentiation, and Maintenance of Native Phenotype. Advanced Functional Materials, 2020, 30, 1908752.	7.8	54
149	C5a causes limited, polymorphonuclear cell-independent, mesenteric ischemia/reperfusion-induced injuryâ†‚,â†‚. Clinical Immunology, 2003, 108, 263-273.	1.4	53
150	cAMP-responsive Element Modulator Î± (CREMÎ±) trans-Represses the Transmembrane Glycoprotein CD8 and Contributes to the Generation of CD3+CD4â^'CD8â^' T Cells in Health and Disease. Journal of Biological Chemistry, 2013, 288, 31880-31887.	1.6	53
151	Cutting Edge: Nanogel-Based Delivery of an Inhibitor of CaMK4 to CD4+ T Cells Suppresses Experimental Autoimmune Encephalomyelitis and Lupus-like Disease in Mice. Journal of Immunology, 2015, 195, 5533-5537.	0.4	53
152	Programmed Cell Death 1 and Helios Distinguish TCR-Î±Î²+ Double-Negative (CD4â^'CD8â^') T Cells That Derive from Self-Reactive CD8 T Cells. Journal of Immunology, 2015, 194, 4207-4214.	0.4	53
153	Selective Loss of Signaling Lymphocytic Activation Molecule Family Member 4â€“Positive CD8+ T Cells Contributes to the Decreased Cytotoxic Cell Activity in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 164-173.	2.9	53
154	PP2A Dephosphorylates Elf-1 and Determines the Expression of CD3Î¶ and FcRÎ³ in Human Systemic Lupus Erythematosus T Cells. Journal of Immunology, 2008, 181, 3658-3664.	0.4	52
155	Glucocorticoids Suppress T Cell Function by Upâ€Regulating MicroRNAâ€98. Arthritis and Rheumatism, 2013, 65, 1882-1890.	6.7	52
156	T Cell Abnormalities in the Pathogenesis of Systemic Lupus Erythematosus: an Update. Current Rheumatology Reports, 2021, 23, 12.	2.1	52
157	Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial. Journal of Autoimmunity, 2022, 130, 102844.	3.0	52
158	Lupus Serum IgG Induces Skin Inflammation through the TNFR1 Signaling Pathway. Journal of Immunology, 2010, 184, 7154-7161.	0.4	51
159	Cutting Edge: Protein Phosphatase 2A Confers Susceptibility to Autoimmune Disease through an IL-17â€“Dependent Mechanism. Journal of Immunology, 2012, 188, 3567-3571.	0.4	51
160	Estrogen Upregulates Cyclic AMP Response Element Modulator Î± Expression and Downregulates Interleukin-2 Production by Human T Lymphocytes. Molecular Medicine, 2012, 18, 370-378.	1.9	51
161	Splicing factor SF2/ASF rescues IL-2 production in T cells from systemic lupus erythematosus patients by activating IL-2 transcription. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1845-1850.	3.3	51
162	Pathogenesis and targeted treatment of skin injury in SLE. Nature Reviews Rheumatology, 2015, 11, 663-669.	3.5	51

#	Article	IF	Citations
163	Brief Report: CD4+ T Cells From Patients With Systemic Lupus Erythematosus Respond Poorly to Exogenous Interleukinâ€2. Arthritis and Rheumatology, 2017, 69, 808-813.	2.9	51
164	Pyruvate dehydrogenase phosphatase catalytic subunit 2 limits Th17 differentiation. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 9288-9293.	3.3	51
165	The Structural Basis of Compstatin Activity Examined by Structure-Function-based Design of Peptide Analogs and NMR. Journal of Biological Chemistry, 2002, 277, 14942-14953.	1.6	50
166	Geldanamycin treatment inhibits hemorrhage-induced increases in KLF6 and iNOS expression in unresuscitated mouse organs: role of inducible HSP70. Journal of Applied Physiology, 2004, 97, 564-569.	1.2	50
167	Lupus Nephritis IgG Induction of Calcium/CalmodulinâEDependent Protein Kinase IV Expression in Podocytes and Alteration of Their Function. Arthritis and Rheumatology, 2016, 68, 944-952.	2.9	50
168	Accelerated Ischemia/Reperfusion-Induced Injury in Autoimmunity-Prone Mice. Journal of Immunology, 2004, 173, 4230-4235.	0.4	49
169	Empowering Regulatory T Cells in Autoimmunity. Trends in Molecular Medicine, 2016, 22, 784-797.	3.5	49
170	Neutrophil FcÎ³RIIA promotes IgG-mediated glomerular neutrophil capture via Abl/Src kinases. Journal of Clinical Investigation, 2017, 127, 3810-3826.	3.9	48
171	Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nature Biomedical Engineering, 2021, 5, 1288-1305.	11.6	47
172	A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Seminars in Arthritis and Rheumatism, 1986, 16, 70-78.	1.6	46
173	Alternative Splicing Factor/Splicing Factor 2 Regulates the Expression of the Î¶ Subunit of the Human T Cell Receptor-associated CD3 Complex. Journal of Biological Chemistry, 2010, 285, 12490-12496.	1.6	46
174	Induction of PP2A BÎ², a regulator of IL-2 deprivation-induced T-cell apoptosis, is deficient in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 12443-12448.	3.3	46
175	Treatment with Anti-Interleukin 23 Antibody Ameliorates Disease in Lupus-Prone Mice. BioMed Research International, 2013, 2013, 1-5.	0.9	46
176	Direct Transfer of p65 into T Lymphocytes from Systemic Lupus Erythematosus Patients Leads to Increased Levels of Interleukin-2 Promoter Activity. Clinical Immunology, 2002, 103, 145-153.	1.4	45
177	Systems biology in systemic lupus erythematosus: Integrating genes, biology and immune function. Autoimmunity, 2006, 39, 705-709.	1.2	45
178	Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice. Arthritis and Rheumatism, 2010, 62, 2424-2431.	6.7	45
179	Spleen tyrosine kinase inhibition prevents tissue damage after ischemia-reperfusion. American Journal of Physiology - Renal Physiology, 2010, 299, G391-G399.	1.6	45
180	A quantitative lateral flow assay to detect complement activation in blood. Analytical Biochemistry, 2015, 477, 78-85.	1.1	45

#	Article	IF	Citations
181	The Cyclic AMP Response Element Modulator Regulates Transcription of the TCR Î¶-Chain. Journal of Immunology, 2005, 175, 5975-5980.	0.4	44
182	cAMP-responsive Element Modulator Î± (CREMÎ±) Contributes to Decreased Notch-1 Expression in T Cells from Patients with Active Systemic Lupus Erythematosus (SLE). Journal of Biological Chemistry, 2012, 287, 42525-42532.	1.6	44
183	T Cell Transcriptomes Describe Patient Subtypes in Systemic Lupus Erythematosus. PLoS ONE, 2015, 10, e0141171.	1.1	44
184	Successful Treatment of Generalized Discoid Skin Lesions With Azathioprine. Archives of Dermatology, 1985, 121, 1323.	1.7	43
185	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specificDNA-binding protein. Biochemical Journal, 1999, 338, 417-425.	1.7	43
186	Forced Expression of the Fc Receptor Î³-Chain Renders Human T Cells Hyperresponsive to TCR/CD3 Stimulation. Journal of Immunology, 2003, 170, 2871-2876.	0.4	42
187	Transcriptional repression of interleukin-2 in human systemic lupus erythematosus. Autoimmunity Reviews, 2006, 5, 118-121.	2.5	42
188	Spleen tyrosine kinase: An Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity, 2010, 43, 48-55.	1.2	42
189	Precision DNA demethylation ameliorates disease in lupus-prone mice. JCI Insight, 2018, 3, .	2.3	42
190	Spleen Tyrosine Kinase (Syk) Regulates Systemic Lupus Erythematosus (SLE) T Cell Signaling. PLoS ONE, 2013, 8, e74550.	1.1	42
191	Novel molecular targets in the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2008, 7, 256-261.	2.5	41
192	Systemic lupus erythematosus serum deposits C4d on red blood cells, decreases red blood cell membrane deformability, and promotes nitric oxide production. Arthritis and Rheumatism, 2011, 63, 503-512.	6.7	41
193	Calcium/Calmodulinâ€Ðependent Kinase IV Facilitates the Recruitment of Interleukinâ€17â€“Producing Cells to Target Organs Through the CCR6/CCL20 Axis in Th17 Cellâ€“Driven Inflammatory Diseases. Arthritis and Rheumatology, 2016, 68, 1981-1988.	2.9	41
194	Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. Clinical Immunology, 2021, 226, 108716.	1.4	41
195	Neuroendocrine Aspects of Chronic Fatigue Syndrome. NeuroImmunoModulation, 2004, 11, 65-74.	0.9	40
196	The serine/threonine protein phosphatase 2A controls autoimmunity. Clinical Immunology, 2018, 186, 38-42.	1.4	40
197	Lupus Nephritis and Other Autoimmune Features in Patients with Diabetes Mellitus Due to Autoantibody to Insulin Receptors. Annals of Internal Medicine, 1985, 102, 176.	2.0	39
198	Association of Deficient Type II Protein Kinase A Activity with Aberrant Nuclear Translocation of the RIIÎ² Subunit in Systemic Lupus Erythematosus T Lymphocytes. Journal of Immunology, 2000, 165, 2830-2840.	0.4	39

#	Article	IF	Citations
199	Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: A new mechanism for TCR ? chain deficiency and abnormal signaling. Journal of Cellular Biochemistry, 2002, 85, 459-469.	1.2	39
200	Human c1 esterase inhibitor attenuates murine mesenteric ischemia/reperfusion induced local organ injury. Journal of Surgical Research, 2003, 115, 247-256.	0.8	39
201	T cell abnormalities in human and mouse lupus: intrinsic and extrinsic. Current Opinion in Rheumatology, 2003, 15, 542-547.	2.0	39
202	T lymphocytes in systemic lupus erythematosus: an update. Current Opinion in Rheumatology, 2004, 16, 548-552.	2.0	39
203	B cells contribute to ischemia/reperfusion-mediated tissue injury. Journal of Autoimmunity, 2009, 32, 195-200.	3.0	39
204	Ubiquitination Regulates Expression of the Serine/Arginine-rich Splicing Factor 1 (SRSF1) in Normal and Systemic Lupus Erythematosus (SLE) T Cells. Journal of Biological Chemistry, 2014, 289, 4126-4134.	1.6	39
205	Recent developments in systemic lupus erythematosus pathogenesis and applications for therapy. Current Opinion in Rheumatology, 2018, 30, 222-228.	2.0	39
206	The role of IL-17 in systemic lupus erythematosus and its potential as a therapeutic target. Expert Review of Clinical Immunology, 2019, 15, 629-637.	1.3	39
207	Activation of the Ets Transcription Factor Elfâ€1 Requires Phosphorylation and Glycosylation. Annals of the New York Academy of Sciences, 2003, 987, 240-245.	1.8	38
208	Effects of C1 Inhibitor on Tissue Damage in a Porcine Model of Controlled Hemorrhage. Shock, 2012, 38, 82-91.	1.0	38
209	Treatment of systemic lupus erythematosus: new advances in targeted therapy. Annals of the New York Academy of Sciences, 2012, 1247, 138-152.	1.8	38
210	Maintenance of Efficacy and Safety of Ustekinumab Through One Year in a Phase <scp>II</scp> Multicenter, Prospective, Randomized, Doubleâ€Blind, Placeboâ€Controlled Crossover Trial of Patients With Active Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2020, 72, 761-768.	2.9	38
211	Characterization of in Vivo Mutated T Cell Clones from Patients with Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology, 1995, 74, 135-142.	2.1	37
212	Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis and Rheumatism, 1997, 40, 980-982.	6.7	37
213	C3d binding to the circumsporozoite protein carboxy-terminus deviates immunity against malaria. International Immunology, 2005, 17, 245-255.	1.8	37
214	Autoimmunity in systemic lupus erythematosus: Integrating genes and biology. Seminars in Immunology, 2006, 18, 230-243.	2.7	37
215	SLAMF6-driven co-stimulation of human peripheral T cells is defective in SLE T cells. Autoimmunity, 2011, 44, 211-218.	1.2	37
216	Low-Dose IL-2 in the Treatment of Lupus. Current Rheumatology Reports, 2016, 18, 68.	2.1	37

#	Article	IF	Citations
217	Downregulation of miR-200a-3p, Targeting CtBP2 Complex, Is Involved in the Hypoproduction of IL-2 in Systemic Lupus Erythematosusâ€“Derived T Cells. Journal of Immunology, 2017, 198, 4268-4276.	0.4	37
218	The RNA-stabilizing Protein HuR Regulates the Expression of Î¶ Chain of the Human T Cell Receptor-associated CD3 Complex. Journal of Biological Chemistry, 2008, 283, 20037-20044.	1.6	36
219	Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis and Rheumatism, 2011, 63, 2755-2763.	6.7	36
220	R-spondin3 prevents mesenteric ischemia/reperfusion-induced tissue damage by tightening endothelium and preventing vascular leakage. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 14348-14353.	3.3	36
221	Proâ€inflammatory selfâ€reactive TÂcells are found within murine TCRâ€Îİ±Î²⁺CD4^{â^'}CD8^{â^'}PDâ€1⁺ cells. European Journal of Immunology, 2016, 46, 1383-1391.	1.6	36
222	The immune podocyte. Current Opinion in Rheumatology, 2019, 31, 167-174.	2.0	36
223	Complement Receptor 2 in the Regulation of the Immune Response. Clinical Immunology and Immunopathology, 1998, 88, 123-132.	2.1	35
224	C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusionâ˜†â˜†The opinions contained herein are the private ones of the authors and are not to be construed as official policy or reflecting the views of the Department of Defense.. Clinical Immunology, 2003, 106, 55-64.	1.4	35
225	Anti-RNP immunity: Implications for tissue injury and the pathogenesis of connective tissue disease. Autoimmunity Reviews, 2007, 6, 232-236.	2.5	35
226	Syk kinase as a treatment target for therapy in autoimmune diseases. Clinical Immunology, 2007, 124, 235-237.	1.4	35
227	Towards the next generation of anti-TNF drugs. Clinical Immunology, 2011, 141, 231-235.	1.4	35
228	The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update. Current Opinion in Rheumatology, 2021, 33, 586-591.	2.0	35
229	Interplay of immune and kidney resident cells in the formation of tertiary lymphoid structures in lupus nephritis. Autoimmunity Reviews, 2021, 20, 102980.	2.5	35
230	Dissociation between Cortisol and Adrenal Androgen Secretion in Patients Receiving Alternate Day Prednisone Therapy. Journal of Clinical Endocrinology and Metabolism, 1987, 65, 24-29.	1.8	34
231	Monoclonal antibodies and fusion proteins in medicine. Journal of Allergy and Clinical Immunology, 2005, 116, 721-729.	1.5	34
232	T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis. Clinical Immunology, 2008, 128, 1-7.	1.4	34
233	Dendritic cell function in lupus: Independent contributors or victims of aberrant immune regulation. Autoimmunity, 2010, 43, 121-130.	1.2	34
234	CREMÎ± overexpression decreases IL-2 production, induces a TH17 phenotype and accelerates autoimmunity. Journal of Molecular Cell Biology, 2012, 4, 121-123.	1.5	34

#	Article	IF	Citations
235	SLAMF6 as a Regulator of Exhausted CD8+ T Cells in Cancer. Cancer Immunology Research, 2019, 7, 1485-1496.	1.6	34
236	Aberrantly glycosylated IgG elicits pathogenic signaling in podocytes and signifies lupus nephritis. JCI Insight, 2021, 6, .	2.3	34
237	Double-negative T cells in autoimmune diseases. Current Opinion in Rheumatology, 2021, 33, 163-172.	2.0	34
238	SAP expression in invariant NKT cells is required for cognate help to support B-cell responses. Blood, 2012, 120, 122-129.	0.6	33
239	A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus. Clinical Immunology, 2014, 150, 192-200.	1.4	33
240	TNF-Î± Regulates Human Plasmacytoid Dendritic Cells by Suppressing IFN-Î± Production and Enhancing T Cell Activation. Journal of Immunology, 2021, 206, 785-796.	0.4	33
241	IL-23 reshapes kidney resident cell metabolism and promotes local kidney inflammation. Journal of Clinical Investigation, 2021, 131, .	3.9	33
242	Is there a link between dysregulated miRNA expression and disease?. Discovery Medicine, 2010, 10, 184-94.	0.5	33
243	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochemical Journal, 2000, 348, 151-158.	1.7	32
244	Spontaneous and pokeweed mitogen-induced plaque-forming cells in systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1981, 21, 172-183.	2.1	31
245	Immunomodulatory treatment in patients with rheumatic diseases: Mechanisms of action. Seminars in Arthritis and Rheumatism, 1987, 17, 24-38.	1.6	31
246	Cd28 expression on t cell subsets in vivo and cd28-mediated t cell response in vitro in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1995, 38, 649-654.	6.7	31
247	Decay accelerating factor (CD55) protects neuronal cells from chemical hypoxia-induced injury. Journal of Neuroinflammation, 2010, 7, 24.	3.1	31
248	Complement and coagulation cascades in trauma. Acute Medicine & Surgery, 2019, 6, 329-335.	0.5	31
249	Interleukin-2 restores the depressed allogeneic cell-mediated lympholysis and natural killer cell activity in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1985, 34, 379-386.	2.1	30
250	Development of hypogammaglobulinemia in a patient with systemic lupus erythematosus. American Journal of Medicine, 1986, 81, 1081-1084.	0.6	30
251	Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. Journal of Pediatrics, 1990, 116, S103-S108.	0.9	30
252	Decay-accelerating factor attenuates remote ischemiaâ€“reperfusion-initiated organ damage. Clinical Immunology, 2007, 124, 311-327.	1.4	30

#	Article	IF	Citations
253	Common variable immune deficiency (CVID) presenting as an autoimmune disease: role of memory B cells. Autoimmunity Reviews, 2008, 7, 309-312.	2.5	30
254	A Novel Inhibitor of the Alternative Pathway of Complement Attenuates Intestinal Ischemia/Reperfusion-Induced Injury. Journal of Surgical Research, 2011, 167, e131-e136.	0.8	30
255	Impaired receptor editing and heterozygous RAG2 mutation in a patient with systemic lupus erythematosus and erosive arthritis. Journal of Allergy and Clinical Immunology, 2015, 135, 272-273.	1.5	30
256	Engagement of SLAMF3 enhances CD4 ⁺ T-cell sensitivity to IL-2 and favors regulatory T-cell polarization in systemic lupus erythematosus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 9321-9326.	3.3	30
257	Gene therapy in the treatment of autoimmune diseases. Journal of Clinical Investigation, 2000, 106, 181-183.	3.9	30
258	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1998, 10, 417-425.	2.0	29
259	Regulation of heat shock protein 72 kDa and 90 kDa in human breast cancer MDA-MB-231 cells. Molecular and Cellular Biochemistry, 2000, 204, 169-178.	1.4	29
260	TRANSCRIPTIONAL REGULATION OF INTERLEKIN 2 IN SLE T CELLS. International Reviews of Immunology, 2004, 23, 333-345.	1.5	29
261	Gammalinolenic Acid and Dihomogammalinolenic Acid Suppress the CD3-Mediated Signal Transduction Pathway in Human T Cells. Clinical Immunology and Immunopathology, 1997, 83, 237-244.	2.1	28
262	Heat stress protection against mesenteric I/R-induced alterations in intestinal mucosa in rats. Journal of Applied Physiology, 2002, 92, 2600-2607.	1.2	28
263	Protein Kinase A Regulatory Subunit Type IIÎ² Directly Interacts with and Suppresses CREB Transcriptional Activity in Activated T Cells. Journal of Immunology, 2003, 171, 3636-3644.	0.4	28
264	A Novel Intronic cAMP Response Element Modulator (CREM) Promoter Is Regulated by Activator Protein-1 (AP-1) and Accounts for Altered Activation-induced CREM Expression in T Cells from Patients with Systemic Lupus Erythematosus. Journal of Biological Chemistry, 2011, 286, 32366-32372.	1.6	28
265	The Role of Platelet Factor 4 in Local and Remote Tissue Damage in a Mouse Model of Mesenteric Ischemia/Reperfusion Injury. PLoS ONE, 2012, 7, e39934.	1.1	28
266	Update on the role of Interleukin 17 in rheumatologic autoimmune diseases. Cytokine, 2015, 75, 207-215.	1.4	28
267	NF-Î²B Regulates the Expression of the Human Complement Receptor 2 Gene. Journal of Immunology, 2002, 169, 6236-6243.	0.4	27
268	Autoimmunity, Complement Activation, Tissue Injury and Reciprocal Effects. , 2003, 7, 149-164.		27
269	Complement Activation in Trauma Patients Alters Platelet Function. Shock, 2016, 46, 83-88.	1.0	27
270	Expression patterns of signaling lymphocytic activation molecule family members in peripheral blood mononuclear cell subsets in patients with systemic lupus erythematosus. PLoS ONE, 2017, 12, e0186073.	1.1	27

#	Article	IF	Citations
271	Platelets orchestrate remote tissue damage after mesenteric ischemia-reperfusion. American Journal of Physiology - Renal Physiology, 2012, 302, G888-G897.	1.6	26
272	Current Insights and Future Prospects for Targeting IL-17 to Treat Patients With Systemic Lupus Erythematosus. Frontiers in Immunology, 2020, 11, 624971.	2.2	26
273	Multiple Transcription Factors Regulate the Inducible Expression of the Human Complement Receptor 2 Promoter. Journal of Immunology, 2001, 166, 6156-6163.	0.4	25
274	New insights into the pathogenesis of systemic lupus erythematosus. Current Rheumatology Reports, 2005, 7, 469-475.	2.1	25
275	The Cyclic AMP Response Element Modulator Î± Suppresses CD86 Expression and APC Function. Journal of Immunology, 2009, 182, 4167-4174.	0.4	25
276	T Cell CD3Î¶ Deficiency Enables Multiorgan Tissue Inflammation. Journal of Immunology, 2013, 191, 3563-3567.	0.4	25
277	Complement receptor of the immunoglobulin superfamily reduces murine lupus nephritis and cutaneous disease. Clinical Immunology, 2015, 160, 286-291.	1.4	25
278	Calcium/Calmodulin Kinase IV Controls the Function of Both T Cells and Kidney Resident Cells. Frontiers in Immunology, 2018, 9, 2113.	2.2	25
279	Cytoprotection and regulation of heat shock proteins induced by heat shock in human breast cancer T47â€Ð cells: role of [Ca 2+] i and protein kinases. FASEB Journal, 1998, 12, 1571-1579.	0.2	24
280	Dexamethasone Modulates TCR Î¶ Chain Expression and Antigen Receptor-Mediated Early Signaling Events in Human T Lymphocytes. Cellular Immunology, 2001, 208, 62-71.	1.4	24
281	Intravenous immunoglobulin attenuates mesenteric ischemiaâ€“reperfusion injury. Clinical Immunology, 2005, 114, 137-146.	1.4	24
282	Ischemia-mediated aggregation of the actin cytoskeleton is one of the major initial events resulting in ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2009, 296, G339-G347.	1.6	24
283	Targeting lymphocyte signaling pathways as a therapeutic approach to systemic lupus erythematosus. Current Opinion in Rheumatology, 2011, 23, 449-453.	2.0	24
284	Platelet-Associated CD40/CD154 Mediates Remote Tissue Damage after Mesenteric Ischemia/Reperfusion Injury. PLoS ONE, 2012, 7, e32260.	1.1	24
285	C4d Deposits on the Surface of RBCs in Trauma Patients and Interferes With Their Function*. Critical Care Medicine, 2014, 42, e364-e372.	0.4	24
286	N-WASP is required for B-cellâ€“mediated autoimmunity in Wiskott-Aldrich syndrome. Blood, 2016, 127, 216-220.	0.6	24
287	C3a Enhances the Formation of Intestinal Organoids through C3aR1. Frontiers in Immunology, 2017, 8, 1046.	2.2	24
288	New insights into the role of renal resident cells in the pathogenesis of lupus nephritis. Korean Journal of Internal Medicine, 2018, 33, 284-289.	0.7	24

#	Article	IF	Citations
289	Cytotoxic antibodies to natural killer cells in systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1982, 24, 179-185.	2.1	23
290	Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clinical Immunology and Immunopathology, 1990, 57, 10-18.	2.1	23
291	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1997, 9, 380-386.	2.0	23
292	Immune cell signaling aberrations in human lupus. Immunologic Research, 1998, 18, 27-39.	1.3	23
293	Genome-Wide Association Study Reveals Genetic Link between Diarrhea-Associated Entamoeba histolytica Infection and Inflammatory Bowel Disease. MBio, 2018, 9, .	1.8	23
294	Current insights and future prospects for the pathogenesis and treatment for rheumatoid arthritis. Clinical Immunology, 2021, 225, 108680.	1.4	23
295	T cell Metabolism in Lupus. Immunometabolism, 2020, 2, .	0.7	23
296	Rheumatic disease syndromes associated with antibodies to the Ro (SS-A) ribonuclear protein. Seminars in Arthritis and Rheumatism, 1987, 16, 237-244.	1.6	22
297	Abnormal Early TCR/CD3-Mediated Signaling Events of a snRNP-Autoreactive Lupus T Cell Clone. Clinical Immunology and Immunopathology, 1998, 88, 305-310.	2.1	22
298	A disease with a complex pathogenesis. Lancet, The, 2001, 358, S65.	6.3	22
299	Protein kinase A enhances, whereas glycogen synthase kinase-3Î² inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. Biochemical Journal, 2002, 363, 127.	1.7	22
300	Protein kinase A enhances, whereas glycogen synthase kinase-3Î² inhibits, the activity of the exon 2-encoded transactivator domain of heterogeneous nuclear ribonucleoprotein D in a hierarchical fashion. Biochemical Journal, 2002, 363, 127-136.	1.7	22
301	Systemic lupus erythematosus: new molecular targets. Annals of the Rheumatic Diseases, 2007, 66, iii65-iii69.	0.5	22
302	Anti-ribonucleoprotein antibodies mediate enhanced lung injury following mesenteric ischemia/reperfusion inRag-1â^'/â^'mice. Autoimmunity, 2007, 40, 208-216.	1.2	22
303	C3d-defined complement receptor-binding peptide p28 conjugated to circumsporozoite protein provides protection against Plasmodium berghei. Vaccine, 2007, 25, 7732-7736.	1.7	22
304	Complement Component C5a Mediates Hemorrhage-Induced Intestinal Damage. Journal of Surgical Research, 2008, 150, 196-203.	0.8	22
305	Decay-Accelerating Factor Attenuates C-Reactive Protein-Potentiated Tissue Injury After Mesenteric Ischemia/Reperfusion. Journal of Surgical Research, 2011, 167, e103-e115.	0.8	22
306	CD3-T Cell Receptor Co-stimulation through SLAMF3 and SLAMF6 Receptors Enhances RORÎ³t Recruitment to the IL17A Promoter in Human T Lymphocytes. Journal of Biological Chemistry, 2012, 287, 38168-38177.	1.6	22

#	Article	IF	Citations
307	Decay-accelerating factor limits hemorrhage-instigated tissue injury and improves resuscitation clinical parameters. Journal of Surgical Research, 2013, 179, 153-167.	0.8	22
308	New therapeutics in systemic lupus erythematosus. Current Opinion in Rheumatology, 2013, 25, 297-303.	2.0	22
309	Pin1â€Targeted Therapy for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2016, 68, 2503-2513.	2.9	22
310	The Regulatory Subunit PPP2R2A of PP2A Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK Signaling Pathway. Journal of Immunology, 2021, 206, 1719-1728.	0.4	22
311	Therapeutic potential of interleukin-2 in autoimmune diseases. Trends in Molecular Medicine, 2022, 28, 596-612.	3.5	22
312	On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): Evidence for the Adam and Eve concept of autoantibody production. Clinical Immunology and Immunopathology, 1992, 64, 177-183.	2.1	21
313	Androstenediol inhibits the trauma-hemorrhage-induced increase in caspase-3 by downregulating the inducible nitric oxide synthase pathway. Journal of Applied Physiology, 2007, 102, 933-941.	1.2	21
314	Expansion of an osteopontinâ€expressing T follicular helper cell subset correlates with autoimmunity inB6.Sle1bmice and is suppressed by the H1â€isoform of the Slamf6 receptor. FASEB Journal, 2013, 27, 3123-3131.	0.2	21
315	Lupus-Prone Mice Fail to Raise Antigen-Specific T Cell Responses to Intracellular Infection. PLoS ONE, 2014, 9, e111382.	1.1	21
316	Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice. Journal of Immunology, 2017, 198, 1846-1854.	0.4	21
317	SLE-Associated Defects Promote Altered T Cell Function. Critical Reviews in Immunology, 2017, 37, 39-58.	1.0	21
318	cAMP Response Element Modulator Î± Induces Dual Specificity Protein Phosphatase 4 to Promote Effector T Cells in Juvenile-Onset Lupus. Journal of Immunology, 2019, 203, 2807-2816.	0.4	21
319	CD38 reduces mitochondrial fitness and cytotoxic T cell response against viral infection in lupus patients by suppressing mitophagy. Science Advances, 2022, 8, .	4.7	21
320	Immunoregulatory aberrations in patients with polyarticular juvenile rheumatoid arthritis. Clinical Immunology and Immunopathology, 1988, 47, 62-74.	2.1	20
321	NaCN-induced chemical hypoxia is associated with altered gene expression. Molecular and Cellular Biochemistry, 2003, 254, 211-216.	1.4	20
322	Geldanamycin prevents hemorrhage-induced ATP loss by overexpressing inducible HSP70 and activating pyruvate dehydrogenase. American Journal of Physiology - Renal Physiology, 2006, 291, G117-G127.	1.6	20
323	Transcription factor Ikaros Represses Protein Phosphatase 2A (PP2A) Expression through an Intronic Binding Site. Journal of Biological Chemistry, 2014, 289, 13751-13757.	1.6	20
324	Decreased Expression of Serine/Arginineâ€Rich Splicing Factor 1 in T Cells From Patients With Active Systemic Lupus Erythematosus Accounts for Reduced Expression of RasGRP1 and DNA Methyltransferase 1. Arthritis and Rheumatology, 2018, 70, 2046-2056.	2.9	20

#	Article	IF	Citations
325	Reactive oxygen species: The Yin and Yang in (auto-)immunity. Autoimmunity Reviews, 2021, 20, 102869.	2.5	20
326	Phenotypes of T lymphocytes in systemic lupus erythematosus: Decreased cytotoxic/suppressor subpopulation is associated with deficient allogeneic cytotoxic responses rather than with concanavalin A-induced suppressor cells. Clinical Immunology and Immunopathology, 1983, 26, 267-276.	2.1	19
327	Oxidative stress is involved in the heat stress-induced downregulation of TCR Î¶ chain expression and TCR/CD3-mediated [Ca2+]i response in human T-lymphocytes. Cellular Immunology, 2002, 215, 151-161.	1.4	19
328	Constitutive NO synthase regulates the Na+/Ca2+ exchanger in human T cells: Role of [Ca2+]i and tyrosine phosphorylation. Journal of Cellular Biochemistry, 2003, 89, 1030-1043.	1.2	19
329	Bridging the gap between autoinflammation and autoimmunity. Clinical Immunology, 2013, 147, 151-154.	1.4	19
330	Mood effects of alternate-day corticosteroid therapy in patients with systemic lupus erythematosus. General Hospital Psychiatry, 1988, 10, 56-60.	1.2	18
331	TCR-Î±/Î² CD4â^' CD8â^' double negative T cells arise from CD8+ T cells. Journal of Leukocyte Biology, 2020, 108, 851-857.	1.5	18
332	Suppression of Serum Interferonâ€Î³ Levels as a Potential Measure of Response to Ustekinumab Treatment in Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2021, 73, 472-477.	2.9	18
333	Skeletal muscle heme oxygenase-1 activity regulates aerobic capacity. Cell Reports, 2021, 35, 109018.	2.9	18
334	PP2A enables IL-2 signaling by preserving IL-2RÎ² chain expression during Treg development. JCI Insight, 2019, 4, .	2.3	18
335	The TRAIL to arthritis. Journal of Clinical Investigation, 2003, 112, 1315-1317.	3.9	18
336	Mitochondria in the Pathogenesis of Systemic Lupus Erythematosus. Current Rheumatology Reports, 2022, 24, 88-95.	2.1	18
337	Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase. Clinical Immunology and Immunopathology, 1990, 57, 19-31.	2.1	17
338	Elevated Soluble CD8 Antigen and Soluble Interleukin-2 Receptors in the Sera of Patients with Juvenile Rheumatoid Arthritis. Clinical Immunology and Immunopathology, 1993, 68, 64-67.	2.1	17
339	Biochemical requirements for the expression of heat shock protein 72 kda in human breast cancer MCF-7 cells. Molecular and Cellular Biochemistry, 1999, 199, 179-188.	1.4	17
340	Resuscitation with lactated Ringer solution limits the expression of molecular events associated with lung injury after hemorrhage. Journal of Applied Physiology, 2005, 98, 550-556.	1.2	17
341	Stability and Translation of TCR Î¶ mRNA Are Regulated by the Adenosine-Uridine-Rich Elements in Splice-Deleted 3â€² Untranslated Region of Î¶-Chain. Journal of Immunology, 2006, 177, 8248-8257.	0.4	17
342	C5-blocking antibody reduces fluid requirements and improves responsiveness to fluid infusion in hemorrhagic shock managed with hypotensive resuscitation. Journal of Applied Physiology, 2007, 102, 673-680.	1.2	17

#	Article	IF	Citations
343	Geldanamycin inhibits hemorrhage-induced increases in caspase-3 activity: role of inducible nitric oxide synthase. Journal of Applied Physiology, 2007, 103, 1045-1055.	1.2	17
344	Adhesion molecule expression precedes brain damages of lupus-prone mice and correlates with kidney pathology. Journal of Neuroimmunology, 2012, 252, 24-32.	1.1	17
345	Engagement of SLAMF2/CD48 Prolongs the Time Frame of Effective T Cell Activation by Supporting Mature Dendritic Cell Survival. Journal of Immunology, 2014, 192, 4436-4442.	0.4	17
346	Signaling Lymphocytic Activation Molecule Family Member 1 Engagement Inhibits T Cellâ€“B Cell Interaction and Diminishes Interleukinâ€6 Production and Plasmablast Differentiation in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 99-108.	2.9	17
347	Gene-marked autologous hematopoietic stem cell transplantation of autoimmune disease. Journal of Clinical Immunology, 2000, 20, 1-9.	2.0	16
348	C1 Inhibitor Limits Organ Injury and Prolongs Survival in Swine Subjected to Battlefield Simulated Injury. Shock, 2016, 46, 177-188.	1.0	16
349	Complement activation and increased expression of Syk, mucin-1 and CaMK4 in kidneys of patients with COVID-19. Clinical Immunology, 2021, 229, 108795.	1.4	16
350	Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells. Current Opinion in Rheumatology, 2023, 35, 107-116.	2.0	16
351	Cytotoxic responses to alloantigens in systemic lupus erythematosus. Journal of Clinical Immunology, 1981, 1, 208-216.	2.0	15
352	Cellular immunity in patients with systemic juvenile rheumatoid arthritis. Clinical Immunology and Immunopathology, 1987, 42, 86-92.	2.1	15
353	Cell signaling and heat shock protein expression. Journal of Biomedical Science, 1996, 3, 379-388.	2.6	15
354	Heat stress downregulates TCR ? chain expression in human T lymphocytes. Journal of Cellular Biochemistry, 2000, 79, 416-426.	1.2	15
355	Abnormal B Cell Signal Transduction in Systemic Lupus Erythematosus. , 2002, 6, 89-104.		15
356	Decay-Accelerating Factor Mitigates Controlled Hemorrhage-Instigated Intestinal and Lung Tissue Damage and Hyperkalemia in Swine. Journal of Trauma, 2011, 71, S151-S160.	2.3	15
357	Platelets, complement and tissue inflammation. Autoimmunity, 2013, 46, 1-5.	1.2	15
358	Metabolic control of T cells in autoimmunity. Current Opinion in Rheumatology, 2020, 32, 192-199.	2.0	15
359	Complement Deposition on the Surface of RBC After Trauma Serves a Biomarker of Moderate Trauma Severity: A Prospective Study. Shock, 2020, 53, 16-23.	1.0	15
360	Transcriptional and post-transcriptional mechanisms are responsible for the increased expression of c-myc protooncogene in lymphocytes from patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1989, 52, 507-515.	2.1	14

#	Article	IF	Citations
361	Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specificDNA-binding protein. Biochemical Journal, 1999, 338, 417.	1.7	14
362	Abnormal T Lymphocyte Signal Transduction in Systemic Lupus Erythematosus. , 2001, 5, 131-150.		14
363	N Ï‰-nitro-l-arginine inhibits inducible HSP-70 via Ca2+, PKC, and PKA in human intestinal epithelial T84 cells. American Journal of Physiology - Renal Physiology, 2002, 282, G415-G423.	1.6	14
364	Down-Regulation of IL-2 Production in T Lymphocytes by Phosphorylated Protein Kinase A-RIIÎ². Journal of Immunology, 2004, 172, 7804-7812.	0.4	14
365	In the Beginning Was Sm. Journal of Immunology, 2006, 176, 1295-1296.	0.4	14
366	Why do women get lupus?. Clinical Immunology, 2012, 144, 53-56.	1.4	14
367	Metabolic control of arthritis: Switch pathways to treat. Science Translational Medicine, 2016, 8, 331fs8.	5.8	14
368	Decreased SAP Expression in T Cells from Patients with Systemic Lupus Erythematosus Contributes to Early Signaling Abnormalities and Reduced IL-2 Production. Journal of Immunology, 2016, 196, 4915-4924.	0.4	14
369	IL-17A Produced by Innate Lymphoid Cells Is Essential for Intestinal Ischemia-Reperfusion Injury. Journal of Immunology, 2017, 199, 2921-2929.	0.4	14
370	IL-23/IL-17 Axis in Inflammatory Rheumatic Diseases. Clinical Reviews in Allergy and Immunology, 2021, 60, 31-45.	2.9	14
371	PPP2R2D suppresses IL-2 production and Treg function. JCI Insight, 2020, 5, .	2.3	14
372	Efficacy and Safety of Ustekinumab in Patients With Active Systemic Lupus Erythematosus: Results of a Phase II Open-label Extension Study. Journal of Rheumatology, 2022, 49, 380-387.	1.0	14
373	Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350. European Journal of Immunology, 2000, 30, 969-973.	1.6	13
374	Exploring complement activation to develop biomarkers for systemic lupus erythematosus. Arthritis and Rheumatism, 2004, 50, 3404-3407.	6.7	13
375	Elf-1 Binds to GGAA Elements on the FcRÎ³ Promoter and Represses Its Expression. Journal of Immunology, 2007, 179, 4884-4889.	0.4	13
376	Identification of Orch3, a Locus Controlling Dominant Resistance to Autoimmune Orchitis, as Kinesin Family Member 1C. PLoS Genetics, 2012, 8, e1003140.	1.5	13
377	CD74 Deficiency Mitigates Systemic Lupus Erythematosusâ€“like Autoimmunity and Pathological Findings in Mice. Journal of Immunology, 2017, 198, 2568-2577.	0.4	13
378	CD25 and Protein Phosphatase 2A Cooperate to Enhance IL-2R Signaling in Human Regulatory T Cells. Journal of Immunology, 2019, 203, 93-104.	0.4	13

#	Article	IF	Citations
379	N-glycosylated IgG in patients with kidney transplants increases calcium/calmodulin kinase IV in podocytes and causes injury. American Journal of Transplantation, 2021, 21, 148-160.	2.6	13
380	Serine Arginine-Rich Splicing Factor 1 (SRSF1) Contributes to the Transcriptional Activation of CD3Î¶ in Human T Cells. PLoS ONE, 2015, 10, e0131073.	1.1	13
381	Recovery of splenic function after gvhd-associated functional asplenia. American Journal of Hematology, 1982, 12, 77-80.	2.0	12
382	Human T-cell leukemia/lymphoma virus I and/or Epstein-Barr virus-infected B-cell lines spontaneously produce acid-labile ?-interferon. Journal of Clinical Immunology, 1985, 5, 340-344.	2.0	12
383	Immunosuppressive Agents and Plasmapheresis in Immunological Disorders. Immunopharmacology and Immunotoxicology, 1985, 7, 1-15.	0.8	12
384	Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: Evidence for idiotypic commonality. Clinical Immunology and Immunopathology, 1989, 53, 113-122.	2.1	12
385	The Role of Complement in the Antiphospholipid Syndrome-Associated Pathology. Clinical Reviews in Allergy and Immunology, 2009, 36, 141-144.	2.9	12
386	CREMÎ± suppresses spleen tyrosine kinase expression in normal but not systemic lupus erythematosus T cells. Arthritis and Rheumatism, 2012, 64, 799-807.	6.7	12
387	Downregulation of CD3Î¶ in NK Cells from Systemic Lupus Erythematosus Patients Confers a Proinflammatory Phenotype. Journal of Immunology, 2018, 200, 3077-3086.	0.4	12
388	Hyaluronic Acid Synthesis Contributes to Tissue Damage in Systemic Lupus Erythematosus. Frontiers in Immunology, 2019, 10, 2172.	2.2	12
389	Curb complement to cure COVID-19. Clinical Immunology, 2020, 221, 108603.	1.4	12
390	Amino Acid Metabolism in Lupus. Frontiers in Immunology, 2021, 12, 623844.	2.2	12
391	OVERVIEW OF CELLULAR IMMUNE FUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2004, , 29-92.		12
392	Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model. Clinical and Experimental Rheumatology, 2015, 33, S15-22.	0.4	12
393	The deacetylase SIRT2 contributes to autoimmune disease pathogenesis by modulating IL-17A and IL-2 transcription. , 2022, 19, 738-750.		12
394	C-MYC proto-oncogene expression in peripheral blood mononuclear cells from patients with primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 1990, 33, 49-56.	6.7	11
395	Effects of an aminosteroid inhibitor of phospholipase C-dependent processes on the TCR-mediated signal transduction pathway in human T cells. Clinical Immunology and Immunopathology, 1995, 77, 59-68.	2.1	11
396	High dose of dexamethasone upregulates TCR/CD3-induced calcium response independent of TCR ? chain expression in human T lymphocytes. Journal of Cellular Biochemistry, 2001, 83, 401-413.	1.2	11

#	Article	IF	Citations
397	DISSECTING THE MOLECULAR MECHANISMS OF TCR Î¶ CHAIN DOWNREGULATION AND T Cell SIGNALING ABNORMALITIES IN HUMAN SYSTEMIC LUPUS ERYTHEMATOSUS. International Reviews of Immunology, 2004, 23, 245-263.	1.5	11
398	Calcium signaling in systemic lupus erythematosus lymphocytes and its therapeutic exploitation. Arthritis and Rheumatism, 2008, 58, 1216-1219.	6.7	11
399	Cellular and metabolic requirements of effector T cells. Nature Reviews Rheumatology, 2016, 12, 74-76.	3.5	11
400	Editorial: Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Frontiers in Immunology, 2019, 10, 199.	2.2	11
401	Cancer immunosurveillance by CD8 T cells. F1000Research, 2020, 9, 80.	0.8	11
402	Immune Abnormalities in the Pathogenesis of Juvenile Rheumatoid Arthritis. Rheumatic Disease Clinics of North America, 1991, 17, 843-857.	0.8	11
403	Epstein-Barr virus transformed B cell lines derived from patients with systemic lupus erythematosus produce a nephritic factor of the classical complement pathway. Clinical Immunology and Immunopathology, 1988, 46, 91-99.	2.1	10
404	Corticotropin-releasing factor induces phosphorylation of phospholipase C-Î³ at tyrosine residues via its receptor 2Î² in human epidermoid A-431 cells. European Journal of Pharmacology, 1998, 363, 203-210.	1.7	10
405	Diabetic Hyperglycemia: A Facilitating Factor in Systemic Capillary Leak. Journal of Surgical Research, 2002, 105, 95-101.	0.8	10
406	Inhibition of Syk activity by R788 in platelets prevents remote lung tissue damage after mesenteric ischemia-reperfusion injury. American Journal of Physiology - Renal Physiology, 2012, 302, G1416-G1422.	1.6	10
407	c-Jun and Ets2 Proteins Regulate Expression of Spleen Tyrosine Kinase in T Cells. Journal of Biological Chemistry, 2012, 287, 11833-11841.	1.6	10
408	What rheumatologists need to know about innate lymphocytes. Nature Reviews Rheumatology, 2016, 12, 658-668.	3.5	10
409	Signaling lymphocyte activation molecule family in systemic lupus erythematosus. Clinical Immunology, 2019, 204, 57-63.	1.4	10
410	Suppressor cells generated from human peripheral mononuclear cells by stimulation with pokeweed mitogen. Cellular Immunology, 1981, 65, 221-229.	1.4	9
411	Kinetics of interleukin-4 induction and interferon-Î³ inhibition of IgE secretion by Epstein-Barr virus-infected human peripheral blood B cells. Cellular Immunology, 1991, 133, 408-419.	1.4	9
412	Nucleotide Sequence of a Human Autoantibody to the Alternative Pathway C3/C5 Convertase (C3NeF). Hybridoma, 1993, 12, 231-237.	0.9	9
413	Modulation of Human T-Lymphocyte Plasma Membrane Ca +2 Permeability by Imidazole Antimycotics. Immunopharmacology and Immunotoxicology, 1996, 18, 237-245.	1.1	9
414	TCR Î¶-Chain Abnormalities in Human Systemic Lupus Erythematosus. , 2004, 102, 049-072.		9

#	Article	IF	Citations
415	A114: Methylprednisolone-Induced Inhibition of miR-155 Expression Increases SOCS1-Driven Suppression of Cytokine Signaling. Arthritis and Rheumatology, 2014, 66, S151-S151.	2.9	9
416	Criteria, criteria all around but not an insight into lupus. Rheumatology, 2021, 60, 3037-3038.	0.9	9
417	Serine/threonine phosphatase PP2A is essential for optimal B cell function. JCI Insight, 2020, 5, .	2.3	9
418	Cholera toxin promotes the proliferation of anti-Î¼ antibody-prestimulated human B cells. Cellular Immunology, 1992, 140, 237-247.	1.4	8
419	Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochemical Journal, 2000, 348, 151.	1.7	8
420	Defective CD3Î¶ chain expression in Herpesvirus saimiri (HVS)-derived T-cell lines in gastric adenocarcinoma. Cellular Immunology, 2005, 238, 113-122.	1.4	8
421	T cell-to-T cell clustering enhances NF-ÎºB activity by a PI3K signal mediated by Cbl-b and Rho. Biochemical and Biophysical Research Communications, 2005, 332, 1133-1139.	1.0	8
422	ADAM9 enhances Th17 cell differentiation and autoimmunity by activating TGF-Î²1. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	8
423	Aneurysm of the ascending aorta in systemic lupus erythematosus: Case report and review of the literature. European Journal of Rheumatology, 2017, 4, 133-135.	1.3	8
424	Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukinâ€2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 1204-1210.	2.9	8
425	Intertwined pathways of complement activation command the pathogenesis of lupus nephritis. Translational Research, 2022, 245, 18-29.	2.2	8
426	Study of the idiotypic response to autoantibody to the alternative pathway convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals. Clinical Immunology and Immunopathology, 1992, 62, 291-294.	2.1	7
427	Overview of cellular immune function in systemic lupus erythematosus. , 2004, , 29-92.		7
428	Systemic lupus erythematosus: From disease pathogenesis to therapy. Drug Discovery Today Disease Mechanisms, 2006, 3, 185-192.	0.8	7
429	Proximal signaling control of human effector CD4 T cell function. Clinical Immunology, 2007, 125, 5-15.	1.4	7
430	Pathology and immunology of lupus glomerulonephritis: can we bridge the two?. International Urology and Nephrology, 2007, 39, 223-231.	0.6	7
431	Brief Report: Increased expression of a short splice variant of CTLAâ€4 exacerbates lupus in MRL/lpr mice. Arthritis and Rheumatism, 2013, 65, 764-769.	6.7	7
432	The role of Syk in cutaneous lupus erythematosus. Experimental Dermatology, 2016, 25, 674-675.	1.4	7

#	Article	IF	Citations
433	Skinâ€“kidney crosstalk in SLE. Nature Reviews Rheumatology, 2021, 17, 253-254.	3.5	7
434	Inhibition of capping of immunoglobulin and concanavalin A receptors by cis-dichlorodiammineplatinum-(II) in mouse spleen cells. Cancer Letters, 1980, 10, 261-267.	3.2	6
435	Induction of monocytic suppression after stimulation of peripheral human mononuclear cells with staphylococcal protein A and Staphylococcus aureus. Cellular Immunology, 1983, 78, 144-151.	1.4	6
436	Enhancement of Human Allogeneic Cytotoxic Responses by Interferons. Immunopharmacology and Immunotoxicology, 1985, 7, 403-415.	0.8	6
437	Pathogenesis of human systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1992, 63, 3.	2.1	6
438	Gene Therapy in Systemic Lupus Erythematosus. Current Gene Therapy, 2005, 5, 677-684.	0.9	6
439	Fas (CD95) ligation inhibits activation of NF-Î²B by targeting p65-Rel A in a caspase-dependent manner. Clinical Immunology, 2006, 121, 47-53.	1.4	6
440	Immune cell signaling in autoimmune diseases. Clinical Immunology, 2017, 181, 1-8.	1.4	6
441	Low-dose Interleukin-2 in the Treatment of Autoimmune Disease. Oncology & Hematology Review, 2014, 10, 157.	0.2	6
442	The TRAIL to arthritis. Journal of Clinical Investigation, 2003, 112, 1315-1317.	3.9	6
443	Lymphocyte subpopulations in patients with systemic lupus erythematosus. Clinical Immunology and Immunopathology, 1984, 31, 181-190.	2.1	5
444	Regulation of Human Cytotoxic Responses by Complement: C3, C3b and C3d Preparations Enhance Human Allogeneic Cytotoxic Responses. Immunopharmacology and Immunotoxicology, 1986, 8, 529-541.	1.1	5
445	Lymphocytes, cytokines, inflammation, and immune trafficking. Current Opinion in Rheumatology, 1994, 6, 461-467.	2.0	5
446	IDENTIFICATION OF DIFFERENTIALLY EXPRESSED GENES IN HUMAN MEMORY (CD45RO+) CD4+T LYMPHOCYTES. Immunological Investigations, 2001, 30, 87-101.	1.0	5
447	Uncovering the Genetics of Systemic Lupus Erythematosus. Molecular Diagnosis and Therapy, 2003, 3, 193-202.	3.3	5
448	New therapeutic approaches in systemic lupus erythematosus. Current Opinion in Rheumatology, 2021, 33, 181-189.	2.0	5
449	Protein phosphatase 2A B55Î² limits CD8+ T cell lifespan following cytokine withdrawal. Journal of Clinical Investigation, 2020, 130, 5989-6004.	3.9	5
450	Inhibition of calcium/calmodulin-dependent protein kinase IV in arthritis: dual effect on Th17 cell activation and osteoclastogenesis. Rheumatology, 2023, 62, 861-871.	0.9	5

#	Article	IF	Citations
451	A Factor Activating Complement via the Alternative Pathway in the Supernatants of B Cell Lines Transformed by Epstein-Barr Virus and in Sera Obtained from Patients with Systemic Lupus erythematosus. International Archives of Allergy and Immunology, 1988, 86, 209-214.	0.9	4
452	Heat-Shock of Normal T-Cells and T-Cell Lines Downregulates the TCR/CD3-Mediated Cytoplasmic CA2+Responses and the Production of Inositol Triphosphate. Immunopharmacology and Immunotoxicology, 1997, 19, 511-521.	1.1	4
453	FcRÎ³ chain does not replace CD3Î¶ chain in CD3Î¶-deficient T lymphocytes of patients with gastric adenocarcinoma. Molecular Immunology, 2007, 44, 2400-2405.	1.0	4
454	Interleukinâ€2 in systemic autoimmunity hits the micro way. Arthritis and Rheumatism, 2012, 64, 3494-3497.	6.7	4
455	Monogenic lupus. International Journal of Clinical Rheumatology, 2014, 9, 543-546.	0.3	4
456	Cyclic AMP Response Element Modulator-Î± Suppresses PD-1 Expression and Promotes Effector CD4+ T Cells in Psoriasis. Journal of Immunology, 2021, 207, 55-64.	0.4	4
457	Alternate-Day Corticosteroid Treatment, Mood and Plasma HVA in Patients with Systemic Lupus erythematosus. Neuropsychobiology, 1988, 19, 17-19.	0.9	3
458	The CR2 receptor (CD21) shows increased expression in the more differentiated cells of an antigen-specific B cell line. Cellular Immunology, 1990, 125, 386-395.	1.4	3
459	Cytokines in Systemic Lupus Erythematosus 2011. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-1.	3.0	3
460	Complement depletion protects lupus-prone mice from ischemia-reperfusion-initiated organ injury. American Journal of Physiology - Renal Physiology, 2013, 304, G283-G292.	1.6	3
461	B Cells in Systemic Lupus Erythematosus. , 1999, , 167-180.		3
462	Melanocyte-secreted fibromodulin constrains skin inflammation in mice injected with lupus serum. Clinical Immunology, 2022, , 109055.	1.4	3
463	Chlorpromazine and Lidocaine Inhibit Antibody-Dependent Cell-Mediated Cytotoxicity but Not Erythrocyte Antibody Rosette Formation. International Archives of Allergy and Immunology, 1980, 61, 344-346.	0.9	2
464	The Alter Ego of Heat Shock Proteins. Clinical Immunology and Immunopathology, 1998, 86, 235-236.	2.1	2
465	Characterization of Distinct Heat Shock- and ThapsigarginInduced Cytoprotective Proteins in FRTL-5 Thyroid Cells. Thyroid, 1999, 9, 1041-1047.	2.4	2
466	Serum Regulates the Expression of Complement Receptor 2 on Human B Cell Lines. Immunopharmacology and Immunotoxicology, 2000, 22, 205-219.	1.1	2
467	IMMUNE CELL SIGNALING AND GENE TRANSCRIPTION IN HUMAN LUPUS: THE TIME HAS COME. International Reviews of Immunology, 2004, 23, 221-224.	1.5	2
468	Systemic lupus erythematosus and Sj??gren??s syndrome. Current Opinion in Rheumatology, 2005, 17, 511-512.	2.0	2

#	Article	IF	Citations
469	Overview of the Pathogenesis of Systemic Lupus Erythematosus. , 2007, , 55-63.		2
470	Post-Transcriptional Regulation of T Cell Receptor zeta Chain in Systemic Lupus Erythematosus. Clinical Immunology, 2007, 123, S66.	1.4	2
471	Cytokines in Systemic Lupus Erythematosus. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	2
472	T Cells. , 2013, , 96-103.		2
473	Nephritic Factor Autoantibodies. , 2014, , 561-565.		2
474	Fat T cells go to the joint. Nature Immunology, 2017, 18, 955-956.	7.0	2
475	OP0041â€...MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY. , 2019, , .		2
476	251â€...Type II but not type I interferon signifies clinical response to ustekinumab in patients with systemic lupus erythematosus. , 2019, , .		2
477	T Lymphocytes Cash Their Value in Clinical Medicine. Trends in Molecular Medicine, 2020, 26, 800-802.	3.5	2
478	FcÏµ receptor type I Î³ chain replaces the deficient T cell receptor Î¶ chain in T cells of patients with systemic lupus erythematosus. , 2001, 44, 1114.		2
479	Methods and Protocols to Study T Cell Signaling Abnormalities in Human Systemic Lupus Erythematosus. Methods in Molecular Biology, 2012, 900, 25-60.	0.4	2
480	The global burden of heterogeneity of lupus erythematosus interventional trials. Journal of Autoimmunity, 2022, 128, 102798.	3.0	2
481	Kidney-Draining Lymph Node Fibrosis Following Unilateral Ureteral Obstruction. Frontiers in Immunology, 2021, 12, 768412.	2.2	2
482	Lymphocytes in the neighborhood: good or bad for the kidney?. Journal of Clinical Investigation, 2022, 132, .	3.9	2
483	Ikaros, Aiolos and other moving targets to treat SLE. Nature Reviews Rheumatology, 2022, 18, 499-500.	3.5	2
484	Immune Cell Signaling and Gene Transcription in Human Systemic Lupus Erythematosus. , 2005, , 263-278.		1
485	Complement in autoimmunity and tissue injury. Autoimmunity, 2006, 39, 355-356.	1.2	1
486	The Role of Interleukin-17 in Systemic Lupus Erythematosus. , 2011, , 391-400.		1

#	Article	IF	Citations
487	Target It All Right, But Do Not Forget the Torchbearer. Circulation, 2015, 131, 1153-1155.	1.6	1
488	OP0278â€…BIOMARKER PROFILING REVEALS NOVEL MECHANISTIC INSIGHTS INTO USTEKINUMAB THERAPEUTIC RESPONSES IN SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		1
489	SNPs talk to genes using landlines: long-range chromatin interactions link genetic risk with epigenetic patterns in Takayasu arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1293-1295.	0.5	1
490	A new checkpoint in lupus. Journal of Allergy and Clinical Immunology, 2019, 143, 1351-1352.	1.5	1
491	Animal Models: Systemic Autoimmune Diseases. , 2020, , 533-551.		1
492	Notch notches lupus. Kidney International, 2020, 97, 251-253.	2.6	1
493	Pathogenesis of lupus. , 2011, , 1289-1294.e1.		1
494	Nephritic Factor Autoantibodies. , 1996, , 540-545.		1
495	Animal Models of Autoimmune Disease. , 2006, , 329-348.		1
496	TARGETING TARGETED TREATMENT FOR IMMUNE AND NON-IMMUNE KIDNEY DISEASES. Transactions of the American Clinical and Climatological Association, 2019, 130, 88-99.	0.9	1
497	Shortage of aspartate in mitochondria fuels arthritis. Nature Immunology, 2021, 22, 1474-1476.	7.0	1
498	Tissue resident cell processes determine organ damage in systemic lupus erythematosus. Clinical Immunology, 2022, 234, 108919.	1.4	1
499	Reduction of Cell Surface T-Cell Receptor by Non-Mitogenic CD3 Antibody to Mitigate Murine Lupus. Frontiers in Immunology, 2022, 13, 855812.	2.2	1
500	Treatment of Discoid Skin Lesions With Azathioprine-Reply. Archives of Dermatology, 1986, 122, 746.	1.7	0
501	Inhibition of ischemia reperfusion-induced intestinal injury and systemic inflammation by a novel complement regulatory protein. Gastroenterology, 2000, 118, A829.	0.6	0
502	Role of HSP70I in heat stress and glutamine protection against mesenteric ischemia/reperfusion (IR)-induced injury in vivo. Gastroenterology, 2000, 118, A1123.	0.6	0
503	Regulation of Complement Receptor Gene Expression. , 2004, , 61-73.		0
504	Role of Complement in Intestinal Ischemia/Reperfusion Induced Injury. , 2004, , 437-449.		0

#	Article	IF	Citations
505	Complement and Autoimmunity. , 2004, , 307-314.		0
506	SLE and SjÃ¶gren syndrome in 2004. Current Opinion in Rheumatology, 2004, 16, 497-498.	2.0	0
507	Systemic Lupus Erythematosus: New Ideas for Diagnosis and Treatment. , 2006, , 249-270.		0
508	NEPHRITIC FACTOR AUTOANTIBODIES. , 2007, , 561-566.		0
509	2006 clinical immunology school on systemic autoimmune diseases. Autoimmunity Reviews, 2007, 6, 203.	2.5	0
510	Sa.5. The Role of Lipid Rafts in the Pathogenesis of Systemic Lupus Erythematosus. Clinical Immunology, 2008, 127, S81.	1.4	0
511	Sa.45. Alternative Splicing Factor/Splicing Factor 2 (ASF/SF2) Regulates the Expression of T Cell Receptor Î¶ chain. Clinical Immunology, 2008, 127, S95.	1.4	0
512	Sa.99. CREB Binds to Demethylated CRE-elements on the PP2AcÎ± Promoter and Induces Its Expression. Clinical Immunology, 2008, 127, S113.	1.4	0
513	T-Cells and Systemic Lupus Erythematosus. , 2011, , 129-142.		0
514	In appreciation of Patricia Katz, PhD and Edward Yelin, PhD, Co-Editors, Arthritis Care & Research, 2005-2011. Arthritis Care and Research, 2011, 63, 787-787.	1.5	0
515	Excellence in Rheumatology 2012 25-28 January Madrid. International Journal of Rheumatic Diseases, 2012, 15, e17-e18.	0.9	0
516	Systemic Lupus Erythematosus, Animal Models. , 2014, , 1134-1141.		0
517	A serine/threonine phosphatase, PP2A, controls autoimmunity. Arthritis Research and Therapy, 2014, 16, A30.	1.6	0
518	T Cells and Autoimmunity. , 2015, , 85-108.		0
519	Principles of Signaling. , 2017, , 408-417.		0
520	T Cells in Autoimmune Diseases. , 2019, , 29-36.		0
521	SP0083â€…MOLECULAR AND METABOLIC EVENTS WHICH UNDERWRITE T CELL PHENOTYPES IN AUTOIMMUNITY. , 2019, , .		0
522	201â€…Ustekinumab targets a novel mechanism of action to treat patients with systemic lupus erythematosus. , 2019, , .		0

#	Article	IF	Citations
523	T Cells. , 2019, , 116-124.		0
524	O9â€...Reduction of interferon-Î³ and elevated baseline cytotoxic gene expression in the blood associate with ustekinumab response in SLE. , 2020, , .		0
525	The Clinical Spectrum of Anti-Insulin Receptor Antibodies and Autoimmune Disease. Journal of Clinical Rheumatology, 2001, 7, 361-362.	0.5	0
526	CTLAâ€4 expression regulation and its functions in systemic lupus erythematosus (SLE). FASEB Journal, 2008, 22, 667.9.	0.2	0
527	Pathogenesis of lupus. , 2015, , 1082-1087.		0